Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...
A popular biologic medicine used to combat autoimmune diseases cost Medicare and its beneficiaries considerably more when the injectable treatment was obtained at pharmacies rather than injected in ...
Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...
Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously (directly ...
Medicare Part B does not typically cover ustekinumab (Stelara) because it is a self-administered drug, but Medicare Part D plans provide cover. Why does Part B not offer coverage? Medicare Part B is ...
GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results